dihexa hgf c met synaptogenesis Activated HGF-c-Met Axis in Head and Neck Cancer Dihexa Peptide - Nationwide Peptides

These timelines reflect typical clinical observations, not guaranteed outcomes

In clinical studies targeting obesity, particularly in the phase 3 trials based on the SURPASS program, tirzepatide demonstrated outstanding weight reduction benefits, with some patients achieving a weight loss of up to 22.5%

Analysis of body composition further demonstrated that Cagrilintide specifically reduced fat mass while preserving lean mass in WT mice

Dec 29, 2025 Cagrilintide is a long-acting amylin receptor agonist that produces 10-12% body weight loss through mechanisms completely different from GLP-1s - dramatically slowing gastric emptying, suppressing appetite via brain amylin receptors, and reducing postprandial glucose